Cargando…
High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer
BACKGROUND: The mesenchymal–epithelial transition (MET) pathway is frequently altered in tumours. The purpose of our study was to determine the prognostic value of tumour MET expression levels in patients with triple-negative breast cancer (TNBC), in order to strengthen the rationale for targeted th...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619063/ https://www.ncbi.nlm.nih.gov/pubmed/23422757 http://dx.doi.org/10.1038/bjc.2013.31 |
_version_ | 1782265457768660992 |
---|---|
author | Zagouri, F Bago-Horvath, Z Rössler, F Brandstetter, A Bartsch, R Papadimitriou, C A Dimitrakakis, C Tsigginou, A Papaspyrou, I Giannos, A Dimopoulos, M-A Filipits, M |
author_facet | Zagouri, F Bago-Horvath, Z Rössler, F Brandstetter, A Bartsch, R Papadimitriou, C A Dimitrakakis, C Tsigginou, A Papaspyrou, I Giannos, A Dimopoulos, M-A Filipits, M |
author_sort | Zagouri, F |
collection | PubMed |
description | BACKGROUND: The mesenchymal–epithelial transition (MET) pathway is frequently altered in tumours. The purpose of our study was to determine the prognostic value of tumour MET expression levels in patients with triple-negative breast cancer (TNBC), in order to strengthen the rationale for targeted therapy of TNBC using MET inhibitors. METHODS: We determined expression of MET in formalin-fixed paraffin-embedded surgical specimens of TNBC by immunohistochemistry. Recurrence-free and overall survival was analysed with Cox models adjusted for clinical and pathological factors. RESULTS: Immunostaining for MET was classified as high in 89 of 170 (52%) tumours. MET expression was more frequently observed in G3 carcinomas (P=0.02) but was not significantly associated to any of the other clinical or pathological parameters. High MET expression predicted shorter survival of the patients. Multivariate Cox proportional hazards regression analyses identified MET to be an independent prognostic factor for recurrence (adjusted hazard ratio (HR) for recurrence 3.43; 95% confidence interval (CI) 1.65–7.12; P=0.001) and death (adjusted HR for death 3.74; 95% CI 1.65–8.46; P=0.002). CONCLUSION: These results provide further evidence that the MET pathway could be exploited as a target for TNBC. |
format | Online Article Text |
id | pubmed-3619063 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-36190632014-03-19 High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer Zagouri, F Bago-Horvath, Z Rössler, F Brandstetter, A Bartsch, R Papadimitriou, C A Dimitrakakis, C Tsigginou, A Papaspyrou, I Giannos, A Dimopoulos, M-A Filipits, M Br J Cancer Molecular Diagnostics BACKGROUND: The mesenchymal–epithelial transition (MET) pathway is frequently altered in tumours. The purpose of our study was to determine the prognostic value of tumour MET expression levels in patients with triple-negative breast cancer (TNBC), in order to strengthen the rationale for targeted therapy of TNBC using MET inhibitors. METHODS: We determined expression of MET in formalin-fixed paraffin-embedded surgical specimens of TNBC by immunohistochemistry. Recurrence-free and overall survival was analysed with Cox models adjusted for clinical and pathological factors. RESULTS: Immunostaining for MET was classified as high in 89 of 170 (52%) tumours. MET expression was more frequently observed in G3 carcinomas (P=0.02) but was not significantly associated to any of the other clinical or pathological parameters. High MET expression predicted shorter survival of the patients. Multivariate Cox proportional hazards regression analyses identified MET to be an independent prognostic factor for recurrence (adjusted hazard ratio (HR) for recurrence 3.43; 95% confidence interval (CI) 1.65–7.12; P=0.001) and death (adjusted HR for death 3.74; 95% CI 1.65–8.46; P=0.002). CONCLUSION: These results provide further evidence that the MET pathway could be exploited as a target for TNBC. Nature Publishing Group 2013-03-19 2013-02-19 /pmc/articles/PMC3619063/ /pubmed/23422757 http://dx.doi.org/10.1038/bjc.2013.31 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Molecular Diagnostics Zagouri, F Bago-Horvath, Z Rössler, F Brandstetter, A Bartsch, R Papadimitriou, C A Dimitrakakis, C Tsigginou, A Papaspyrou, I Giannos, A Dimopoulos, M-A Filipits, M High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer |
title | High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer |
title_full | High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer |
title_fullStr | High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer |
title_full_unstemmed | High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer |
title_short | High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer |
title_sort | high met expression is an adverse prognostic factor in patients with triple-negative breast cancer |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619063/ https://www.ncbi.nlm.nih.gov/pubmed/23422757 http://dx.doi.org/10.1038/bjc.2013.31 |
work_keys_str_mv | AT zagourif highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer AT bagohorvathz highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer AT rosslerf highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer AT brandstettera highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer AT bartschr highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer AT papadimitriouca highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer AT dimitrakakisc highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer AT tsigginoua highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer AT papaspyroui highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer AT giannosa highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer AT dimopoulosma highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer AT filipitsm highmetexpressionisanadverseprognosticfactorinpatientswithtriplenegativebreastcancer |